The Company has five objectives for its Quell partnership strategy.
- Support NeuroMetrix efforts to build the Quell brand in the North America market
- Make Quell technology and brand available worldwide
- Accelerate Quell R&D
- Expand Quell clinical study program
- Increase NeuroMetrix shareholder value
The Company is currently engaged in discussions around several types of partnerships including an e-commerce collaboration in the US market, licensing and/or distribution rights to European and Asian markets, and R&D collaborations. Although the likelihood and timing of any particular partnership is uncertain, the Company believes that one or more partnerships may evolve over the next year.
"The development of strategic and business partnerships is a key component of our Quell strategy. They offer the potential of a larger resource pool to more rapidly advance many facets of our Quell program,” said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. “We are encouraged by the high level of interest we have experienced from large medical device and consumer healthcare companies.”
About Quell Wearable Pain Relief TechnologyTM
Quell is FDA cleared and designed for the millions of people suffering from chronic pain. The advanced wearable technology delivers 100% drug free relief and is available without a prescription. Quell can be used during the day while active, and at night while sleeping. Quell gives users the option to start, stop, and adjust therapy discreetly via their smartphone. It also provides therapy utilization and advanced sleep tracking. Quell is available at select healthcare professionals and retailers. To find a Quell retailer, visit the Store Locator at QuellRelief.com.
NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders and diabetes. The company’s lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer